LY 3045697

Drug Profile

LY 3045697

Alternative Names: LY-3045697

Latest Information Update: 02 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 01 Sep 2013 Eli Lilly completes a phase I trial in Healthy volunteers in the Netherlands (NCT01821703)
  • 25 Jul 2013 Eli Lilly completes a phase I volunteer trial in Netherlands (NCT01750853)
  • 09 Jul 2013 Eli Lilly initiates enrolment in a phase I trial in Cardiovascular disorders (healthy volunteers) in Netherlands (NCT01821703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top